Articles tagged with Drug Studies
Researchers found that combining sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists reduces the risk of major adverse cardiovascular events and chronic kidney disease progression by 11% and 33%, respectively. The study suggests using this combination to further improve outcomes in patients with typ...
A Phase 2 clinical trial demonstrated the effectiveness of OXO-001 in increasing embryo implantation, pregnancy and live birth rates among infertile women. The study showed significant improvements in biochemical, clinical and ongoing pregnancy rates, with a notable increase in live birth rates.
A new study by the University of Toronto Nursing found that over one million industry-sponsored events took place in the US in 2022, with a focus on physician and nurse practitioner interactions. These events were linked to specific pharmaceutical products, indicating their potential impact on prescribing practices.
The University of Texas at Arlington's Junha Jeon is developing transition metal-free cross-coupling technologies using arynes to deliver medications safely and effectively. This project aims to improve the production of drugs, particularly for cancer treatment, by reducing impurities left behind by metals.
A study of over 183,000 adults found that certain antidepressants can cause significant weight gain or loss, while others have little to no effect. Bupropion was consistently associated with the least weight gain among 8 first-line antidepressants, which may impact medication adherence and patient treatment decisions.
A new study found that bupropion is associated with the least amount of weight gain among common antidepressant medications, with users being 15-20% less likely to gain clinically significant weight. The research also highlights the varying weight gain effects of different antidepressants.
Researchers at UCSF have discovered a way to turn ordinary white fat cells into beige fat cells that burn calories, opening the door to developing new weight-loss drugs. The approach uses a protein called KLF-15 and may avoid side effects associated with current treatments.
The NIH is sponsoring a Phase 1 trial of an experimental nasal COVID-19 vaccine that may offer enhanced protection against emerging variants. The trial will enroll 60 adult participants and assess the safety and immune response of the vaccine candidate, MPV/S-2P.
A study published in Trends in Urology and Men's Health found that several treatments have been effective in treating delayed ejaculation, including vibration stimulation therapy and psychotherapy. The research highlights the need for health professionals to be aware of a patient's full medical and sexual history and offers hope for mi...
Researchers have identified three new variants of MDMA as promising alternatives for controlled psychotherapeutic use, retaining therapeutic potential while reducing side effects. The new compounds show a similar effect on clinical target structures in the brain and are broken down more favorably, resulting in fewer toxic products.
A University of Otago-led trial found that extended-release ketamine tablets significantly improved depressive symptoms in adults with treatment-resistant depression. The tablets showed good tolerability and minimal side effects compared to traditional injection or nasal spray methods.
A new study by UC San Francisco's ANSIRH program found that patients who received care remotely for medication abortion had similar outcomes to those who got ultrasounds and in-person care. The researchers analyzed the experiences of over 500 patients and found a high success rate for the
A new ketamine tablet form has shown promise in treating severe depression with negligible side effects and convenience. The study found that patients on the strongest dose of ketamine had the best results compared to placebo.
A new study led by researchers from the University of Pennsylvania School of Medicine developed a novel approach to assess medication-related liver injury. By analyzing real-world health care data, they found that some medications' levels of danger to the liver are being misclassified.
Researchers have developed a novel drug therapy for obstructive sleep apnea (OSA), which has shown significant improvements in reducing breathing interruptions and improving overall health. The treatment targets both respiratory and metabolic complications, providing a promising alternative to existing therapies.
Researchers at MD Anderson Cancer Center have identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), reducing cellular senescence and tissue inflammation. TERT restoration also spurred new neuron formation with improved memory and enhanced neuromuscular function.
A study by TUM researchers discovered four subtypes of Amyotrophic Lateral Sclerosis (ALS) with different molecular processes, including sex differences. The findings suggest repurposing an approved cancer drug targeting the MAPK pathway as a promising therapeutic approach for ALS.
A landmark clinical trial collaboration has reported significant improvements in neurobehavioral and functional outcomes for children with moderate to advanced stages of Sanfilippo syndrome. The study found anakinra, a recombinant interleukin-1 receptor antagonist, to be safe and effective in reducing disease symptoms.
A new study published in PLOS ONE found that lifetime LSD use is associated with a higher likelihood of severe psychological distress after losing one's job. The study analyzed data from over 15,000 adults and found that prior LSD use was linked to greater symptoms of psychological distress.
A preliminary clinical trial found that nicotinamide riboside, a form of vitamin B3, increased the walking endurance of patients with peripheral artery disease by over 57 feet. The study suggests that nicotinamide riboside may be a new option for treating chronic leg disease.
Scientists have created mirror-image cyclodextrins in the laboratory, which could make it easier to formulate and deliver complex medications. These discoveries may also lead to improved treatment of cardiovascular diseases caused by atherosclerotic plaques.
A study of 450 community outpatient mental health facilities found that approximately one-third offered medications for opioid use disorder. The availability of these medications highlights the need for further research on uptake and effective referral models.
The number of US individuals with chronic hypertension in pregnancy increased significantly, while medication treatment remained low, according to a new study. The findings highlight the need for improved maternal health strategies to address high blood pressure and cardiovascular complications.
A global study and meta-analysis confirm pantoprazole's effectiveness in preventing upper GI bleeding in critically ill adults on a breathing machine. The research, led by McMaster University, shows that pantoprazole reduces the risk of clinically important upper GI bleeding but has no significant impact on mortality.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Scientists found that a small increase in temperature can drastically change mutation frequency in E. coli bacteria, facilitating resistance development. The results suggest using fever control or antimicrobial drugs at higher temperatures to mitigate antibiotic resistance.
A study found that neural balance, measured by the E/I ratio, is associated with brain maturity and better cognitive ability. Research suggests that as children develop, their E/I ratios decrease, leading to improved performance in cognitive tests.
Researchers developed microscopic robots that swim through lungs to deliver cancer-fighting medication directly to metastatic tumors. The approach inhibited tumor growth and spread, improving survival rates compared to control treatments.
This review bridges traditional wisdom and modern science to examine the safety, efficacy, and bioactivity of herbal medicines. It highlights successful case studies where herbal remedies enhance patient outcomes when used alongside conventional treatments.
The fungus secretes enzymes that transform tea chemical components through oxidation, degradation, and condensation reactions. This results in high-quality fermented teas with enhanced flavor and health benefits.
Coptis teeta Wall. has been traditionally used to treat malaria, stomach ache, diarrhea, skin conditions, eye disorders, and gastrointestinal issues. The plant's compounds have shown antibacterial activity, anti-inflammatory effects, and potential in treating chronic conditions like diabetes and cancer.
A clinical trial shows that a combination of injectable naltrexone and extended-release oral bupropion reduces methamphetamine use for up to 12 weeks. The study found a significant increase in methamphetamine-negative urine tests among participants receiving the two-drug therapy.
A new study published in the New England Journal of Medicine found that crinecerfont reduces adrenal androgen production by half in adults with Congenital Adrenal Hyperplasia (CAH), allowing for lower doses of corticosteroids. This could lead to fewer long-term side effects associated with high-dose corticosteroid use.
The number of calls to US poison centers has increased sharply, with a 233.9% rise in intentional exposures among adults. The severity of unintentional exposures also increased, with 37.4% more cases resulting in severe harm and 65.3% more deaths.
The NIH is investing $30 million in a pilot program called CARE for Health, which aims to integrate clinical research with community-based primary care. The initiative seeks to improve health outcomes by providing access to clinical research and expanding opportunities for participation in clinical trials.
A systematic review and meta-analysis of over 20,000 patients found that one in six to seven patients will experience discontinuation symptoms directly caused by stopping the medication. Severe symptoms occurred in about 3% of patients, with certain antidepressants increasing the risk.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
A clinical trial discovered that the drug abrocitinib, approved for eczema treatment, significantly reduced symptoms of patients with severe itching diseases. Abrocitinib improved symptoms in both prurigo nodularis and chronic pruritus of unknown origin by 78% and 54%, respectively.
A meta-analysis of 15 randomized studies found that patients taking GLP-1 medications experienced only mild differences in gastric emptying, delaying solid food by about 36 minutes. The findings suggest it may be safe to continue these medications before surgery without a high risk of aspiration.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.
A new study by ECOG-ACRIN Cancer Research Group aimed to address disparities in breast cancer care for Black patients. The trial found that tailoring research to the needs of underserved groups is effective, with docetaxel showing lower rates of peripheral neuropathy and dose reductions compared to paclitaxel.
The phase 2 clinical trial of BXCL701 in combination with pembrolizumab showed a 50% progression-free survival rate and significant reductions in CA19-9 markers, indicating potential anti-cancer effects. The treatment has also shown low blood pressure as the main side effect.
A recent study has identified over 300 distinct types of bacteria in Roman Baths water, including those with antibiotic-producing capabilities. These microorganisms show promise as a potential source of novel natural products to combat antibiotic resistance.
Wake Forest University School of Medicine has received a $1.5 million grant to study bone microarchitecture in patients following bariatric surgery. The researchers will use high-resolution peripheral quantitative computed tomography (HR-pQCT) imaging to assess bone loss and muscle changes after weight-loss surgery.
A clinical trial led by Mount Sinai researchers shows zodasiran, an RNA inhibitor targeting ANGPTL3, significantly reduces various types of cholesterol and triglycerides. The therapy also lowers apolipoprotein B, a lipid-transporting protein linked to heart disease.
A new study published in JAMA suggests that kidneys from deceased donors on dialysis can be safely transplanted into recipients, reducing the pool of available donors. The study found no significant difference in transplant failure or death rates between recipients of kidneys from donors with and without dialysis.
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
Researchers have developed a novel solubilizer for olaparib, a selective PARP inhibitor, using π-π-stacked poly (ɛ-caprolactone)-based micelles. The studies found that these micelles improved the solubility of olaparib and exhibited sustained release behavior in vitro.
A new study found that nearly 3% of healthy adolescents aged 11-15 have used commercial CBD products for medicinal or health-related reasons. The study identified predictors of commercial CBD use, including older age, certain health conditions, and parental attitudes towards cannabis use.
Certain combinations of medication or psychotherapy with transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) are supported by clinical studies for major depressive disorder (MDD) treatment. Researchers recommend more sophisticated trial designs to move the field forward.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
Researchers report that dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in COPD patients with type 2 inflammation. The study's findings are promising for these patients, who have a high risk of exacerbations.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Researchers at Ochsner Health have developed SRP-001, a novel medication that leverages unique biological mechanisms to alleviate pain without typical side effects. The first-in-human Phase 1 trial confirms SRP-001's safety and tolerability, paving the way for its progression to further clinical stages.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers found a significant disparity between the placebo group and those receiving varenicline, with a quit rate of 45% compared to 30% in the placebo group. The study suggests that varenicline may be effective in helping adults quit using e-cigarettes.
A review of clinical studies suggests that combining TMS or tDCS with certain types of psychotherapy or medication can lead to greater symptom reduction in patients with major depressive disorder. However, the research has limitations and more sophisticated trial designs are needed to move the field forward.
Researchers have developed a new weight loss drug that combines GLP-1 with molecules blocking the NMDA receptor, exploiting its effects on appetite control and neuroplasticity. This approach shows promise for greater weight loss in mice than existing medications.